Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) in a research note issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Up 6.3 %

BCLI stock opened at $2.72 on Tuesday. The firm has a 50 day moving average of $2.80 and a 200-day moving average of $3.03. The firm has a market capitalization of $99.24 million, a P/E ratio of -4.25 and a beta of 0.05. Brainstorm Cell Therapeutics has a 12 month low of $2.52 and a 12 month high of $4.46.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) last announced its quarterly earnings data on Monday, May 16th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). During the same quarter in the prior year, the firm earned ($0.19) earnings per share. Sell-side analysts predict that Brainstorm Cell Therapeutics will post -0.61 EPS for the current year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geneos Wealth Management Inc. purchased a new stake in shares of Brainstorm Cell Therapeutics during the fourth quarter valued at $40,000. Abner Herrman & Brock LLC increased its position in Brainstorm Cell Therapeutics by 13.7% in the first quarter. Abner Herrman & Brock LLC now owns 265,000 shares of the biotechnology company’s stock worth $890,000 after buying an additional 32,000 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Brainstorm Cell Therapeutics by 27.5% during the first quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock valued at $827,000 after purchasing an additional 53,036 shares in the last quarter. State Street Corp increased its stake in Brainstorm Cell Therapeutics by 10.8% in the 1st quarter. State Street Corp now owns 96,060 shares of the biotechnology company’s stock worth $323,000 after buying an additional 9,357 shares in the last quarter. Finally, S.C. Financial Services Inc. boosted its stake in Brainstorm Cell Therapeutics by 66.6% in the 2nd quarter. S.C. Financial Services Inc. now owns 25,471 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 10,186 shares during the period. Institutional investors own 12.28% of the company’s stock.

About Brainstorm Cell Therapeutics

(Get Rating)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Recommended Stories

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.